Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.80M USD | Price to earnings Ratio 0.23 | 1Y Target Price 7.5 |
Price to earnings Ratio 0.23 | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.69 | 52 Weeks Range 0.14 - 3.97 | Updated Date 10/13/2025 |
52 Weeks Range 0.14 - 3.97 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -207.41% | Return on Equity (TTM) -612.3% |
Valuation
Trailing PE 0.23 | Forward PE - | Enterprise Value 7234223 | Price to Sales(TTM) - |
Enterprise Value 7234223 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 42905339 | Shares Floating 33384790 |
Shares Outstanding 42905339 | Shares Floating 33384790 | ||
Percent Insiders 0.26 | Percent Institutions 1.74 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex, Inc. is a clinical-stage gene therapy company founded in 2009. It focuses on developing therapies for cancer and diabetes.
Core Business Areas
- Oncoprex Immunogene Therapy: Genprex's lead drug candidate, REQORSAu2122 (quaratusugene ozeplasmid), is based on the company's Oncoprexu2122 platform, which uses a plasmid to deliver tumor suppressor genes to cancer cells to treat non-small cell lung cancer.
- Diabetes Gene Therapy: Genprex is developing gene therapy treatments for Type 1 and Type 2 diabetes
Leadership and Structure
Genprex is led by a management team with experience in the pharmaceutical and biotech industries. Its organizational structure includes departments for research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- REQORSAu2122 (quaratusugene ozeplasmid): REQORSAu2122 is Genprex's lead drug candidate, currently undergoing clinical trials for Non-Small Cell Lung Cancer. Market share data is currently not available. Competitors: AstraZeneca (Tagrisso), Merck (Keytruda).
- GPX-002 (Type 1 Diabetes program): GPX-002 is being researched as gene therapy for Type 1 Diabetes. Market share data is not yet available. Competitors: Vertex Pharmaceuticals (developing cell therapies).
Market Dynamics
Industry Overview
The gene therapy market is rapidly expanding, driven by advancements in biotechnology and increasing investment in research and development. The oncology and diabetes fields are areas of intense focus.
Positioning
Genprex aims to position itself as a leader in gene therapy for cancer and diabetes, focusing on innovative treatments that address unmet medical needs. Its competitive advantage lies in its proprietary Oncoprexu2122 platform.
Total Addressable Market (TAM)
The TAM for lung cancer and diabetes treatments is substantial, estimated in billions of dollars annually. Genprex is positioned to capture a portion of this market with successful clinical trials and FDA approval.
Upturn SWOT Analysis
Strengths
- Proprietary Oncoprexu2122 platform technology
- Targeting large markets with unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new and existing therapies
Competitors and Market Share
Key Competitors
- AZN
- MRK
- VRTX
Competitive Landscape
Genprex faces competition from established pharmaceutical companies with greater resources and existing approved therapies. Genprex's advantages are its proprietary technology and focus on unmet medical needs, but it needs to prove its approach clinically.
Growth Trajectory and Initiatives
Historical Growth: Genprex's historical growth is linked to its research and development progress, particularly the advancement of REQORSAu2122 through clinical trials.
Future Projections: Future growth depends on the success of clinical trials, regulatory approvals, and potential partnerships.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials for REQORSAu2122.
Summary
Genprex is a clinical-stage gene therapy company focused on cancer and diabetes, with its lead candidate REQORSAu2122 undergoing clinical trials. Its success hinges on positive clinical trial results and securing partnerships to fund its operations. The company faces significant competition from larger, established pharmaceutical companies. Genprex has a proprietary platform and targets significant unmet medical needs, providing opportunities for future growth, but is also dependent on regulatory approval and financial resources.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Genprex Inc. Investor Relations
- SEC Filings
- Industry Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.genprex.com |
Full time employees 15 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.